3 recruiting, 2 completed, 2 terminated, 1 active not recruiting. 6 Phase 1, 5 Phase 2, 1 Phase 3.
Follow High-risk Myelodysplastic Syndrome: new trials by email Literature Review of High-risk Myelodysplastic Syndrome trials Research Report on High-risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS ATRN-119, Decitabine - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-30 | 2026-11-02 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias CBX-250 - High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Crossbow Therapeutics, Inc. | 72 | 2025-07-16 | 2026-03-16 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML RVU120 - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | Phase 2 | Terminated | Ryvu Therapeutics SA | 62 | 2024-01-23 | 2026-09-16 |
| Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies VIP943 (QW), VIP943 (BIW) - Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Vincerx Pharma, Inc. | 36 | 2023-09-13 | 2024-11-15 |
| The Patient Cohort of the National Center for Precision Medicine in Leukemia Biobanking - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Recruiting | Assistance Publique - Hôpitaux de Paris | 3000 | 2022-03-28 | 2024-05-29 | |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome RVU120(SEL120) - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Terminated | Ryvu Therapeutics SA | 51 | 2019-09-04 | 2026-09-18 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Bemcentinib - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 2 | Completed | GWT-TUD GmbH | 45 | 2018-12-20 | 2021-12-21 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias TH-302 - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Threshold Pharmaceuticals | 40 | 2010-06-01 | 2015-05-07 |
Leukemia, Myeloid, Acute (11) · Myelodysplastic Syndromes (3) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myelomonocytic, Chronic (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bone Marrow Diseases (1) · Burkitt Lymphoma (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Myeloproliferative Disorders (1) · Neoplasm Metastasis (1) · Recurrence (1)
Hemic and Lymphatic Diseases (11) · Leukemia, Myeloid (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Hematologic Diseases (10) · Leukemia (9) · Bone Marrow Diseases (6) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3)
Azacitidine (1) · Busulfan (1) · CPX-351 (1) · Cytarabine (1) · Decitabine (1) · TH 302 (1) · Thiotepa (1) · bemcentinib (1) · fludarabine (1) · fludarabine phosphate (1) · ruxolitinib (1)
Ryvu Therapeutics SA (3) · Ascentage Pharma Group Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Crossbow Therapeutics, Inc. (1) · GWT-TUD GmbH (1) · Threshold Pharmaceuticals (1) · University of Birmingham (1) · Vincerx Pharma, Inc. (1) · Washington University School of Medicine (1)
United States (6) · France (4) · Poland (3) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Briggs Morrison, MD (1) · Charles Craddock, Professor (1) · Geoffrey L Uy, MD (1) · Marina Konopleva, MD, PhD (1) · Uwe Platzbecker, Prof. (1) · Yifan Zhai, MD, PhD (1)
2025 (1), P50CA171963 (1)